Library | 
№ compounds | 
Content description | 
| ChemBridge DIVERSet and CNS-Set | 30 000 | Combinatorial chemistry collection | 
| ChemDiv diversity collection | 50 040 | Combinatorial chemistry collection | 
| Tripos Structures collection | 6 000 | Combinatorial chemistry collection (old) | 
| Specs Consortium Collection | 30 000 | Combinatorial chemistry collection (modern) | 
| Sigma LOPAC1280 | 1 280 | Library of Pharmacologically Active Compounds. Is most commonly used to validate new drug discovery assays and characterize orphan receptors | 
| Tocris Tocriscreen Mini | 1 120 | Many compounds are unique to Tocris | 
| ChemDiv Peptidomimetic library | 15 614 | Peptide mimicking small compounds | 
| ~100 000 | European Chemical Biology Library( ECBL) commercial diversity compound collection | 
Library | 
№ compounds | 
Description | 
| FIMM oncology collections | >1 000 | Oncology set of approved and emerging investigational oncology drugs, compounds available also for proof-of-principle experiments | 
| FIMM metabolic library | 183 | Targeting major metabolic pathways (mitochondria, energy, lipids, proteins and nucleotides) | 
| Comprehensive anti-Cancer small-Compound Library (C3L) | 620 | Oncology set of approved and emerging investigational oncology drugs (max 10 uM concentration for assay plates available) | 
| Prestwick Chemical Library | 1 520 | FDA-approved & EMA-approved drugs | 
| FDA-approved drugs ENZO | 640 | FDA-approved drugs | 
| SPECTRUM MicroSource | 2 000 | The Drug Components (50%); The Natural Products (30%); Other Bioactive Components (20%) | 
| NIH Clinical collection | 446 | The NCC consists almost entirely of experimental drugs that have been in phase I-III clinical trials and have not been represented in other arrayed collections | 
| NCI (National Cancer Institute) collection | 2 500 | Cancer drug derivative collection and natural products (4.8%) | 
Library | 
№ compounds | 
Description | 
| FO | 528 | FIMM oncology collection, a comprehensive collection of approved and emerging investigational oncology drugs in 5 concentrations each (FO6B is the latest version) | 
| FM | 142 | FIMM myeloma-specific collection (5 conc.) | 
| FA | 151 | FIMM AML-specific panel (5 conc.) | 
| QA | 40 | AML-specific drugs in 7 concentrations for HT flow cytometry | 
FIMM/HTB distributes aliquots of available chemical compounds to academic research groups in Finland for a small fee covering the actual compound costs and handling.
A list of available chemical compounds can be found here:
All compound aliquot, custom drugged plate and DSRT set reservations/orders should be done two weeks in advance via 
For further information contact us at 
Please be prepared to provide the following information:
We hand out only unopened tubes/boxes of reagents (CTG, CTB, CellTox etc.) and empty assay plates (20 plates/box). We will still continue ordering big bulks for the better prices.